Compounds > formic acid

Page last updated: 2024-10-16

formic acid and Rhinitis, Allergic, Seasonal

formic acid has been researched along with Rhinitis, Allergic, Seasonal in 1 studies

formic acid: RN given refers to parent cpd
formic acid : The simplest carboxylic acid, containing a single carbon. Occurs naturally in various sources including the venom of bee and ant stings, and is a useful organic synthetic reagent. Principally used as a preservative and antibacterial agent in livestock feed. Induces severe metabolic acidosis and ocular injury in human subjects.

Rhinitis, Allergic, Seasonal: Allergic rhinitis that occurs at the same time every year. It is characterized by acute CONJUNCTIVITIS with lacrimation and ITCHING, and regarded as an allergic condition triggered by specific ALLERGENS.

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Trompetter, I	1
Lebert, J	1
Weiß, G	1

Clinical Trials (1)

Trial Overview

Trial			Phase	Enrollment	Study Type	Start Date	Status
Observational Study With PASCALLERG ® in Patients With Hay Fever[NCT01660737]				123 participants (Actual)	Observational	2012-02-29	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change of Symptom Bronchial Complaints (Pre-post)

Request Scale (0=not present, 1=mild, 2=moderate, 3=strong) (NCT01660737)
Timeframe: Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 4 weeks after baseline)

Intervention	participants (Number)
	improved	unchanged	deterioreated
PASCALLERG® Tablets in Patients With Hay Fever	44	7	3

Change of Symptom Burning Eyes (Pre-post)

Request Scale (0=not present, 1=mild, 2=moderate, 3=strong) (NCT01660737)
Timeframe: Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 4 weeks after baseline)

Intervention	participants (Number)
	improved	unchanged	deteriorated
PASCALLERG® Tablets in Patients With Hay Fever	68	6	2

Change of Symptom Dry Eyes (Pre- Post)

Request Scale (0=not present, 1=mild, 2=moderate, 3=strong) (NCT01660737)
Timeframe: Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 4 weeks after baseline)

Intervention	participants (Number)
	improved	unchanged	deteriorated
PASCALLERG® Tablets in Patients With Hay Fever	36	9	0

Change of Symptom Headache (Pre-post)

Request Scale (0=not present, 1=mild, 2=moderate, 3=strong) (NCT01660737)
Timeframe: Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 4 weeks after baseline)

Intervention	participants (Number)
	improved	unchanged	deteriorated
PASCALLERG® Tablets in Patients With Hay Fever	38	15	0

Change of Symptom Itching Eyes (Pre- Post)

Request Scale (0=not present, 1=mild, 2=moderate, 3=strong) (NCT01660737)
Timeframe: Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 4 weeks after baseline)

Intervention	participants (Number)
	improved	unchanged	deteriorated
PASCALLERG® Tablets in Patients With Hay Fever	87	10	4

Change of Symptom Rhinitis (Pre-post)

Request Scale (0=not present, 1=mild, 2=moderate, 3=strong) (NCT01660737)
Timeframe: Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 4 weeks after baseline)

Intervention	participants (Number)
	improved	unchanged	deteriorated
PASCALLERG® Tablets in Patients With Hay Fever	89	8	5

Change of Symptom Sneezing (Pre-post)

Request Scale (0=not present, 1=mild, 2=moderate, 3=strong) (NCT01660737)
Timeframe: Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 4 weeks after baseline)

Intervention	participants (Number)
	improved	unchanged	deteriorated
PASCALLERG® Tablets in Patients With Hay Fever	87	13	7

Change of Symptom Tearing Eyes (Pre-post)

Request Scale (0=not present, 1=mild, 2=moderate, 3=strong) (NCT01660737)
Timeframe: Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 4 weeks after baseline)

Intervention	participants (Number)
	improved	unchanged	deteriorated
PASCALLERG® Tablets in Patients With Hay Fever	70	7	5

Change of Symtom Fatigue / Tiredness

Request Scale (0=not present, 1=mild, 2=moderate, 3=strong) (NCT01660737)
Timeframe: Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 4 weeks after baseline)

Intervention	participants (Number)
	improved	unchanged	deteriorated
PASCALLERG® Tablets in Patients With Hay Fever	77	11	5

Efficacy of Pascallerg

Request of Efficacy using a 4-stage scale (very good efficacy, good efficacy, moderate efficacy, no efficacy) (NCT01660737)
Timeframe: appr. 4 weeks after baseline (after appr. 4 weeks of treatment)

Intervention	participants (Number)
	Very good efficacy (symptoms complete decline)	Good efficacy (symptoms clearly improved)	Moderate efficacy (smptoms slightly improved)	No efficacy (symptoms unchanged o worsend)	No data available
PASCALLERG® Tablets in Patients With Hay Fever	60	44	15	2	2

Numerical Rating Scale Well Beeing (Pre- Post)

Influence of allergy on the general well-being (scale from 0-no influence to 10 strong influence) (NCT01660737)
Timeframe: Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 4 weeks after baseline)

Intervention	participants (Number)
	improved	unchanged	detoriorated
PASCALLERG® Tablets in Patients With Hay Fever	109	4	2

Tolerability of Pascallerg

Request of Tolerability using a 2-stage scale (very good tolerability, bad tolerability) (NCT01660737)
Timeframe: app. 4 weeks after baseline (treatment app. for 4 weeks)

Intervention	participants (Number)
	Very good	Bad tolerability
PASCALLERG® Tablets in Patients With Hay Fever	122	1

Other Studies

1 other study available for formic acid and Rhinitis, Allergic, Seasonal

Article	Year
Homeopathic complex remedy in the treatment of allergic rhinitis: results of a prospective, multicenter observational study. Forschende Komplementarmedizin (2006), 2015, Volume: 22, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Chromium Compounds; Chronic Disease; Complementar	2015